Baricitinib for use in monogenic interferonopathies (adults and children 2 years and over)

Baricitinib is recommended to be available as a treatment option through routine commissioning for adults and children 2 years and over with monogenic interferonopathies within the criteria set out in the commissioning policy

NHS England